Aether Industries Ltd

- The company successfully raised Rs. 750 crores through Qualified Institutional Placement (QIP) by issuing 80.12 lakh equity shares to 36 qualified institutional buyers. - The funds from this QIP will be deployed for CAPEX for Site 3 and Site 5, working capital requirements, and general corporate purposes. - There is no mention of any new or upcoming fundraising through debt or equity beyond this QIP in the provided pages. - The company is currently focusing on utilizing this raised capital for expansion and operational needs.

- Raised Rs. 750 crores through Qualified Institutional Placement (QIP) for CAPEX on Site 3, Site 5, working capital, and general corporate purposes. - Site 5: Planned CAPEX of Rs. 330 crores for large-scale and contractual exclusive manufacturing; asset turn targeted at 2X. - Construction underway for Site 3++ with 3 new molecules scheduled to launch in next 12-14 months. - Site 4 project initiated for strategic supply agreement with a major US oil field services company; commissioning expected to start contributing from Q4 FY24, full contribution in FY25. - Investment focus on expanding R&D infrastructure: plans to double R&D building and manpower within next 1-2 years. - Strategic acquisitions under preliminary discussion in US and Europe to enhance R&D capabilities and footprint, no finalization yet. - Licensing agreement with Saudi Aramco Technologies finalized for commercializing sustainable converge polyols technology.

- Anticipated robust growth in FY24, though raw material price crash delayed momentum to Q3-Q4 (Page 10). - Expected recovery and growth in agrochemical sector demand from Q3-Q4 after current destocking phase (Page 9, 18-19). - Site 3 maturity expected to generate approx. Rs. 400 crores revenue over next 2 years (Page 9-10). - Launch of new products in Site 3+, Site 3++, Site 4, and Site 5 to drive growth in upcoming years (Page 5). - Oil field services contract starting contribution from Q4 FY24, full impact in FY25, with 16,000 MT/year volume and Rs. 300+ crores revenue potential (Page 4, 12). - Diversification across pharma, agrochemical, material science, and oil & gas sectors to balance portfolio and stimulate growth (Page 18-19). - Long-term focus on R&D pipeline and innovation to sustain new product launches and market expansion (Pages 5, 19).

- Q2 and Q3 expected to be challenging quarters due to agro sector slowdown and inventory destocking; recovery anticipated in Q3 and Q4. - Management optimistic about normalization and growth in Q3-Q4, targeting better momentum for the year-end. - Revenue target of around INR 1000 crores for FY24 is still expected, though some delay possible due to market conditions. - The launch of new molecules at Site 3 and Site 3++, along with large-scale manufacturing and contractual services, to drive future revenue growth. - The oil field services business, expected to contribute from Q4 FY24 and FY25, has strong revenue potential (over Rs. 300 crores/year) with EBITDA margins around 28-30%. - EBITDA margins maintained around 29% with focus on high-value product mix to protect profitability despite pricing pressure. - R&D pipeline and diversification into material sciences, flavor & fragrance, oil & gas sectors underpin long-term growth. - Cost advantages via solar power plant and reduced utility costs expected to support margins.

- The company has signed a Letter of Intent (LOI) with one of the top three global oil field services companies in the US. - This LOI includes four strategic products with a combined volume of approximately 16,000 metric tons per year, with expected revenues north of Rs. 300 crores annually starting fiscal 2025. - Partial contributions from this orderbook are expected in the last quarter of the current fiscal year. - The company has also launched multiple new products across various sites, including Site 3 and Site 3++, with a pipeline expected to contribute significantly over the next 1-2 years. - Site 3 at maturity is projected to generate around Rs. 400 crores in revenue. - Contract renewals and new product launches are anticipated to pick up in Q2-Q4 of the current fiscal year, with Q2 remaining challenging. - Discussions on small acquisitions and expansion of R&D capabilities are ongoing but not finalized.